Atropine: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - " ==" to "==") |
ClaireLewis (talk | contribs) No edit summary |
||
| (9 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | |||
*Type: [[Anticholinergic]] | |||
*Routes of Administration: IV/IM/IO/SC, endotracheal, nebulized, PO, topical/ophthalmic | |||
*Common Trade Names: Atropine, Atreza, SalTropine, AtroPen, IsoptoAtropine | |||
==Adult Dosing== | ==Adult Dosing== | ||
* | ===[[Symptomatic bradyarrhythmia]] or [[AV block]]=== | ||
* | *0.5 mg IV rapid push q3-5m (max = 0.04 milligram/kg) | ||
===[[Cardiac arrest]] (bradyasystolic)=== | |||
*1mg IV/IM/subQ/endotracheally q3-5m | |||
===[[Organophosphate toxicity]]=== | |||
*1-3mg IV/IM/SC/endotracheally q10-30m, max 3 doses | |||
===[[IBS]], [[PUD]]=== | |||
*0.4-0.6 mg PO or IV/IM/SC q4-6h | |||
===Cycloplegia/mydriasis induction=== | |||
*1-2 drops of 1% solution 1-3 times daily | |||
==Pediatric dosing== | |||
===[[Symptomatic bradyarrhythmia]] or [[AV block]]=== | |||
*0.01-0.03 mg/kg IV/IO q1-2h | |||
===[[Cardiac arrest]] (bradyasystolic)=== | |||
*0.01-0.03 mg/kg IV/IM/subQ/endotracheally | |||
===[[Organophosphate toxicity]]=== | |||
*0.01-0.03 mg/kg IV/IM/subQ/endotracheally | |||
===[[IBS]], [[PUD]]=== | |||
*0.01 mg/kg (max 0.4 mg or 0.3 mg/m2) PO/SC q4-6h | |||
===Cycloplegia/mydriasis induction=== | |||
*1-2 drops of 1% solution 1-3 times daily | |||
== | ==Special Populations== | ||
* | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
*Lactation: Infant risk cannot be ruled out | |||
*Renal Dosing: no adjustment | |||
*Hepatic Dosing: no adjustment | |||
*Ineffective in cardiac transplant patients | |||
==Contraindications== | |||
*Allergy to class/drug | |||
*Primary glaucoma or predisposition to narrow anterior chamber angle glaucoma | |||
==Adverse Reactions== | |||
===Serious=== | |||
*[[Cardiac dysrhythmia]], [[tachyarrhythmia]] | |||
*If given slowly or in amounts <0.5mg, may cause paradoxical bradycardia | |||
*Increased O2 consumption | |||
*[[Hypotension]] | |||
*[[Coma]] | |||
*Respiratory depression | |||
*[[Glaucoma]] | |||
===Common=== | |||
*Constipation, xerostomia | |||
*Blurred vision, decreased lacrimation, eye pain, photophobia, superficial keratitis | |||
==Pharmacology== | |||
*Half-life: 2.5 hrs | |||
*Metabolism: hepatic | |||
*Excretion: renal | |||
*Onset of action (IV) = 2-4min | |||
*Duration of action (IV) = 5hr | |||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Parasympatholytic | *Parasympatholytic | ||
**Increases sinus/AV conduction | **Increases sinus/AV conduction | ||
==See Also== | ==See Also== | ||
*[[Antiarrhythmics]] | *[[Antiarrhythmics]] | ||
*[[Critical care quick reference]] | *[[Critical care quick reference]] | ||
*[[Anticholinergic toxicity]] | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:Cardiology]] [[Category:Toxicology]] | ||
Latest revision as of 20:18, 19 September 2019
General
- Type: Anticholinergic
- Routes of Administration: IV/IM/IO/SC, endotracheal, nebulized, PO, topical/ophthalmic
- Common Trade Names: Atropine, Atreza, SalTropine, AtroPen, IsoptoAtropine
Adult Dosing
Symptomatic bradyarrhythmia or AV block
- 0.5 mg IV rapid push q3-5m (max = 0.04 milligram/kg)
Cardiac arrest (bradyasystolic)
- 1mg IV/IM/subQ/endotracheally q3-5m
Organophosphate toxicity
- 1-3mg IV/IM/SC/endotracheally q10-30m, max 3 doses
IBS, PUD
- 0.4-0.6 mg PO or IV/IM/SC q4-6h
Cycloplegia/mydriasis induction
- 1-2 drops of 1% solution 1-3 times daily
Pediatric dosing
Symptomatic bradyarrhythmia or AV block
- 0.01-0.03 mg/kg IV/IO q1-2h
Cardiac arrest (bradyasystolic)
- 0.01-0.03 mg/kg IV/IM/subQ/endotracheally
Organophosphate toxicity
- 0.01-0.03 mg/kg IV/IM/subQ/endotracheally
IBS, PUD
- 0.01 mg/kg (max 0.4 mg or 0.3 mg/m2) PO/SC q4-6h
Cycloplegia/mydriasis induction
- 1-2 drops of 1% solution 1-3 times daily
Special Populations
- Pregnancy Rating: C
- Lactation: Infant risk cannot be ruled out
- Renal Dosing: no adjustment
- Hepatic Dosing: no adjustment
- Ineffective in cardiac transplant patients
Contraindications
- Allergy to class/drug
- Primary glaucoma or predisposition to narrow anterior chamber angle glaucoma
Adverse Reactions
Serious
- Cardiac dysrhythmia, tachyarrhythmia
- If given slowly or in amounts <0.5mg, may cause paradoxical bradycardia
- Increased O2 consumption
- Hypotension
- Coma
- Respiratory depression
- Glaucoma
Common
- Constipation, xerostomia
- Blurred vision, decreased lacrimation, eye pain, photophobia, superficial keratitis
Pharmacology
- Half-life: 2.5 hrs
- Metabolism: hepatic
- Excretion: renal
- Onset of action (IV) = 2-4min
- Duration of action (IV) = 5hr
Mechanism of Action
- Parasympatholytic
- Increases sinus/AV conduction
